ArticleReviews in obstetrics & gynecology2011
Ovarian cancer screening and early detection in the general population.
Article in Reviews in obstetrics & gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 122 citations in OpenAlex.
- Trial
- Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Trial
- Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.Cancers · 2026Review
- Integration of label-free surface enhanced Raman spectroscopy (SERS) of extracellular vesicles (EVs) with Raman tagged labels to enhance ovarian cancer diagnostics.Biosensors & bioelectronics · 2025Article
- Role of HE4 in evaluation of adnexal masses and its comparison with CA125, ROMA and RMI in premenopausal women.African health sciences · 2024Observational
- Review
- Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review.BMJ oncology · 2024Article
- Liability, risks, and recommendations for ultrasound use in the diagnosis of obstetrics diseases.Heliyon · 2023Review
- Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.Scientific reports · 2023Article
- Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.International journal of molecular sciences · 2023Article
- Recurrence and 5-year survival rate in patients with borderline ovarian tumors and related factors in Kurdistan.European journal of translational myology · 2022Article
- MiR-135b improves proliferation and regulates chemotherapy resistance in ovarian cancer.Journal of molecular histology · 2022Article
- Early-Stage Detection of Ovarian Cancer Based on Clinical Data Using Machine Learning Approaches.Journal of personalized medicine · 2022Article
- Dysregulation of lncRNA-miRNA-mRNA Interactome as a Marker of Metastatic Process in Ovarian Cancer.Biomedicines · 2022Article
- Multi-component redox system for selective and potent antineoplastic activity towards ovarian cancer cells.Biochemical and biophysical research communications · 2022Article
- Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery.Cancer biomarkers : section A of Disease markers · 2022Review
- CircATRNL1 and circZNF608 Inhibit Ovarian Cancer by Sequestering miR-152-5p and Encoding Protein.Frontiers in genetics · 2022Article
- Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies.Advanced biomedical research · 2022Article
- circ_C20orf11 enhances DDP resistance by inhibiting miR-527/YWHAZ through the promotion of extracellular vesicle-mediated macrophage M2 polarization in ovarian cancer.Cancer biology & therapy · 2021Article
- The mitochondrial landscape of ovarian cancer: emerging insights.Carcinogenesis · 2021Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, the estimated annual incidence of ovarian cancer is 204,000, with 125,000 deaths. In developed countries, ovarian cancer remains the most lethal of all gynecologic malignancies. One of the reasons for the high fatality rate is that more than 70% of women with ovarian cancer are diagnosed with advanced disease. There is a close correlation between stage at presentation and survival; therefore, early detection of ovarian cancer represents the best hope for mortality reduction and long-term disease control. There is preliminary evidence that screening can improve survival, but the impact of screening on mortality from ovarian cancer is still unclear. The proteomic approach has yielded encouraging preliminary findings, but these findings are not mature enough for clinical use. At this time, clear recommendations cannot be made on the basis of the available data.
Indexed as
Identifiers
21629494PMC3100094W17587699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.